• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 3. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 4. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

Introduction to rac Albuterol-d9 (CAS No. 1173021-73-2)

rac Albuterol-d9 (CAS No. 1173021-73-2) is a deuterated form of the well-known bronchodilator Albuterol. This compound is extensively used in pharmaceutical research, particularly in the development and testing of new drugs and formulations. The deuterium labeling of Albuterol provides several advantages, including enhanced stability and improved pharmacokinetic properties, making it a valuable tool in various scientific applications.

The chemical structure of rac Albuterol-d9 is characterized by the substitution of hydrogen atoms with deuterium atoms, which are isotopes of hydrogen with an additional neutron. This modification results in a heavier molecule that exhibits distinct physical and chemical properties compared to its non-deuterated counterpart. The deuterium labeling can be strategically placed at specific positions within the molecule to achieve desired effects, such as increased metabolic stability or altered binding affinities.

In recent years, the use of deuterated compounds has gained significant attention in the pharmaceutical industry due to their potential to improve drug efficacy and safety. For instance, a study published in the Journal of Medicinal Chemistry highlighted the benefits of deuterium labeling in enhancing the metabolic stability of drugs, thereby extending their half-life and reducing the frequency of dosing required. This is particularly relevant for compounds like Albuterol, which are used to manage conditions such as asthma and chronic obstructive pulmonary disease (COPD).

The pharmacological properties of rac Albuterol-d9 are similar to those of its non-deuterated form, but with notable differences in metabolic pathways. The β2-adrenergic receptor agonist activity of Albuterol is retained, making it effective in relaxing bronchial smooth muscle and improving airflow. However, the deuterium labeling can slow down the rate of metabolism, leading to a more sustained release and potentially reduced side effects.

Clinical trials involving deuterated compounds have shown promising results in terms of safety and efficacy. A phase II clinical trial evaluating a deuterated version of a bronchodilator similar to Albuterol-d9 demonstrated a significant reduction in adverse events compared to the non-deuterated form. These findings suggest that deuterium labeling can be a valuable strategy for optimizing drug performance and patient outcomes.

The synthesis of rac Albuterol-d9 involves several steps, including the selective deuteration of specific positions on the albuterol molecule. Advanced techniques such as catalytic deuteration and isotopic exchange reactions are commonly employed to achieve high levels of deuteration efficiency and purity. The resulting compound is then subjected to rigorous quality control measures to ensure its suitability for use in pharmaceutical research.

In addition to its applications in drug development, rac Albuterol-d9 is also used as an internal standard in analytical methods for quantifying albuterol levels in biological samples. The stable isotopic label provides a reliable reference point for accurate and precise measurements, which is crucial for pharmacokinetic studies and therapeutic drug monitoring.

The environmental impact of deuterated compounds like rac Albuterol-d9 is another important consideration. Deuteration does not significantly alter the environmental fate or toxicity profile of the parent compound, but it can influence biodegradation rates and bioaccumulation potential. Therefore, ongoing research is focused on understanding these aspects to ensure the safe use and disposal of deuterated pharmaceuticals.

In conclusion, rac Albuterol-d9 (CAS No. 1173021-73-2) represents an important advancement in the field of pharmaceutical research. Its unique properties make it a valuable tool for developing more effective and safer drugs, particularly for respiratory conditions. As research continues to uncover new applications and benefits, the role of deuterated compounds like rac Albuterol-d9 is likely to expand further in both academic and industrial settings.

• 147663-30-7(Albuterol Dimer Ether, 75%)
• 24085-03-8(N-Benzyl Albuterol)
• 34391-04-3((R)-Salbutamol)
• 18559-94-9(rac Albuterol)
• 149222-15-1(Albuterol Dimer)
• 96948-64-0(t-Butylnorsynephrine)
• 18910-70-8(O-Methyl Albuterol)
• 754926-25-5(O-Ethyl Albuterol)
• 182676-90-0(5-Hydroxy albuterol)
• 18910-68-4(3-Dehydroxy Salbutamol)